PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28420440
OWN - NLM
STAT- In-Process
DA  - 20170419
LR  - 20170421
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Apr 18
TI  - Immune response after autologous hematopoietic stem cell transplantation in type 
      1 diabetes mellitus.
PG  - 90
LID - 10.1186/s13287-017-0542-1 [doi]
AB  - BACKGROUND: This study explored the details of the immune response after
      autologous hematopoietic stem cell transplantation (AHSCT) treatment in type 1
      diabetes mellitus. METHODS: Peripheral blood mononuclear cells (PBMCs) from 18
      patients with type 1 diabetes mellitus were taken at baseline and 12 months after
      AHSCT or insulin-only therapy. The lymphocyte proliferation, mRNA expression and 
      secretion of pro-inflammatory and anti-inflammatory cytokines belonging to
      T-helper type 1 (Th1), T-helper type 17 (Th17) and regulatory T (Treg) cells in
      PBMC culture supernatants were assessed. RESULTS: Compared with patients
      receiving insulin-only treatment, the patients receiving AHSCT treatment showed
      better residual C-peptide secretion, lower anti-GAD titers and less exogenous
      insulin dosages after 12 months of follow-up. AHSCT treatment was associated with
      significantly reduced Th1 and Th17 cell proportions as well as decreased
      IFN-gamma, IL-2, IL-12p40 and IL-17A levels in the PBMC culture supernatants (all
      P < 0.05). Although there was no significant Treg cell expansion after AHSCT
      treatment, we observed increased IL-10, TGF-beta and Foxp3 mRNA expression and
      increased TGF-beta levels. However, we found no significant changes in the T-cell
      subpopulations after insulin treatment, except for higher IL-12p40 mRNA
      expression and a lower proportion of Treg cells. CONCLUSIONS: AHSCT treatment was
      associated with decreased expansion and function of Th1 and Th17 cells, which may
      explain the better therapeutic effect of AHSCT compared with the traditional
      intensive insulin therapy. TRIAL REGISTRATION: Clinicaltrials.gov NCT00807651 .
      Registered 18 December 2008.
FAU - Ye, Lei
AU  - Ye L
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China.
FAU - Li, Li
AU  - Li L
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China.
FAU - Wan, Bing
AU  - Wan B
AD  - The Shanghai Institute of Immunology, Institutes of Medical Sciences, Shanghai
      Jiao-tong University School of Medicine and Key Laboratory of Stem Cell Biology, 
      Institute of Health Sciences, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences & SJTUSM, Shanghai, People's Republic of China.
FAU - Yang, Minglan
AU  - Yang M
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China.
FAU - Hong, Jie
AU  - Hong J
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China.
FAU - Gu, Weiqiong
AU  - Gu W
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China. [email protected]
FAU - Wang, Weiqing
AU  - Wang W
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China.
FAU - Ning, Guang
AU  - Ning G
AD  - The Department of Endocrinology and Metabolism, Ruijin Hospital, Shanghai
      Jiao-tong University School of Medicine, Shanghai Institution of Endocrine and
      Metabolism Diseases, Endocrine and Metabolic E-Institutes of Shanghai
      Universities and Key Laboratory for Endocrinology and Metabolism of Chinese
      Health Ministry, No. 197 Ruijin 2nd Road, Shanghai, 200025, People's Republic of 
      China.
AD  - The Chinese Academy of Sciences, Shanghai Jiao Tong University School of
      Medicine, Shanghai Institutes for Biological Sciences, Laboratory of
      Endocrinology and Metabolism, Institute of Health Sciences, Shanghai, People's
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170418
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
PMC - PMC5395765
OTO - NOTNLM
OT  - Hematopoietic stem cell
OT  - Immune response
OT  - Regulartory T cell
OT  - Th1 cell
OT  - Th17 cell
OT  - Type 1 diabetes mellitus
EDAT- 2017/04/20 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/20 06:00
PHST- 2016/09/16 [received]
PHST- 2017/03/23 [accepted]
PHST- 2017/02/10 [revised]
AID - 10.1186/s13287-017-0542-1 [doi]
AID - 10.1186/s13287-017-0542-1 [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2017 Apr 18;8(1):90. doi: 10.1186/s13287-017-0542-1.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>